Healthcare Realty Trust heads into its July 30 earnings with short sellers rebuilding positions, analysts cautiously lifting targets, and a divergence opening between the stock's gradual recovery and the Street's still-tentative conviction.
The most notable move this week comes from the analyst community. UBS raised its target to $21 from $20 this morning while keeping a Neutral rating — the second UBS lift in two months, having initiated coverage at $18 in late April. That incremental upward drift is consistent with the broader pattern since Q1 results: Wells Fargo, RBC Capital, Scotiabank, and Citi have all nudged targets higher, and Raymond James reinitiated with an Outperform and a $24 target in mid-June, the most bullish call in the recent cluster. The mean price target is now $21.17 against a close of $20.65 — modest upside that reflects a Street still in "show-me" mode rather than one chasing a re-rating. Factor scores underline the caution: the analyst recommendation differential ranks in the 94th percentile, suggesting the recent upgrades represent a genuine tilt toward positive bias, but the EPS momentum scores — ranked 5th and 2nd percentile over 30 and 90 days — tell a bleak near-term earnings story.
Short positioning has built quietly over the past month, though the borrow market shows no stress. Short interest edged to roughly 5% of free float, up about 11% over 30 days, with shares short climbing from 15.7 million at the start of June to 17.5 million now. That pace of accumulation is worth watching ahead of the July 30 print. Yet the borrow environment remains completely relaxed — availability is near 645% of existing short interest, meaning there are roughly six-and-a-half shares available to borrow for every one already borrowed. Cost to borrow has also been falling, dropping more than 21% on the week to under 0.40%. There is no squeeze dynamic here. Options confirm the calm: the put/call ratio of 0.088 is barely above its 20-day average and sits at a negligible z-score, signalling options traders are not bracing for a sharp move in either direction.
The bull-versus-bear debate is well-established. Bulls point to Healthcare Realty's outpatient-focused portfolio, capital recycling from asset dispositions that have reduced leverage, and a tenant base in a structurally growing part of healthcare delivery. Bears counter that FFO per unit fell 9.3% quarter-over-quarter in the last print, missing consensus — the core concern being that dispositions improve the balance sheet but do not, by themselves, fix per-unit productivity. The EV/EBITDA multiple around 16.3x is not demanding for the sector, and the price-to-book at 1.77x is reasonable, but the negative earnings yield and stretched EV/EBIT make fundamental valuation arguments difficult until FFO growth returns. The dividend history in the snapshot is stale (last data from mid-2022), so current yield-based framing cannot be responsibly made here.
On the ownership side, the registry is notably institutional-heavy. BlackRock and Cohen & Steers each hold roughly 15% of shares. Activist-linked Starboard Value holds just under 2%, unchanged as of last quarter. Insider activity over the past 90 days shows a net purchase position in share terms — a director bought 10,000 shares at $18.09 in March — though the CEO sold $642,000 of stock in April, and the Chief Accounting Officer sold a further $525,000 in late June. The insider picture is mixed rather than directional.
The last two earnings events both produced meaningful positive reactions: a 4.7% one-day gain and 7.8% five-day gain after the most recent print, and a similar pattern the quarter before. With the stock up 5% over the past month and short interest quietly accumulating into the July 30 date, what to watch is whether the next FFO print shows any stabilisation in per-unit metrics — because that is the specific number the bears are anchored to, and any improvement there is what the Raymond James Outperform and the cluster of raised targets are implicitly betting on.
See the live data behind this article on ORTEX.
Open HR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
